Mean Change in Best-Corrected Visual Acuity (BCVA) (Early Treatment of Diabetic Retinopathy Study [ETDRS] Letters) From Baseline to Week 24
Timeframe: Baseline and Week 24
Show 38 moreShow less
Proportion of Participants with Absence of Intraretinal Fluid and Subretinal Fluid Over Time
Proportion of Participants with Resolution of Macular Leakage on Fluorescein Angiography (FA) at Week 24
Proportion of Participants with Resolution of Macular Leakage on FA at Week 48
Proportion of Participants with Resolution of Macular Leakage on FA at Week 96
Mean Change in Vascular Leakage Area on FA in the Macula From Baseline Over Time
Mean Change From Baseline in Macular Ischemic Nonperfusion Area as Assessed by Optical Coherence Tomography Angiography (OCT-A)
Proportion of Participants Requiring Panretinal Photocoagulation
Mean Number of Intravitreal (IVT) Injections from Week 48 to Week 96
Proportion of Participants on a Personalized Treatment Interval (PTI) of Every 4 Weeks (Q4W) at Week 96
Proportion of Participants on a Personalized Treatment Interval (PTI) of Every 8 Weeks (Q8W) at Week 96
Proportion of Participants on a Personalized Treatment Interval (PTI) of Every 12 Weeks (Q12W) at Week 96
Proportion of Participants on a Personalized Treatment Interval (PTI) of Every 16 Weeks (Q8W) at Week 96
Mean Change in BCVA (ETDRS letters) from Baseline Over Time
Proportion of Participants who Gain ≥5 ETDRS Letters from Baseline at Week 24
Proportion of Participants who Gain ≥10 ETDRS Letters from Baseline at Week 24
Proportion of Participants who Gain ≥15 ETDRS Letters from Baseline at Week 24
Proportion of Participants who Gain ≥5 ETDRS Letters from Baseline Over Time
Proportion of Participants who Gain ≥10 ETDRS Letters from Baseline Over Time
Proportion of Participants who Gain ≥15 ETDRS Letters from Baseline Over Time
Proportion of Participants who Lose ≥5 ETDRS Letters from Baseline at Week 24
Proportion of Participants who Lose ≥10 ETDRS Letters from Baseline at Week 24
Proportion of Participants who Lose ≥15 ETDRS Letters from Baseline at Week 24
Proportion of Participants who Lose ≥5 ETDRS Letters from Baseline Over Time
Proportion of Participants who Lose ≥10 ETDRS Letters from Baseline Over Time
Proportion of Participants who Lose ≥15 ETDRS Letters from Baseline Over Time
Proportion of Participants with BCVA Snellen Equivalent of 20/20 or Better at Week 24
Proportion of Participants with BCVA Snellen Equivalent of 20/20 or Better Over Time
Proportion of Participants with BCVA Snellen Equivalent of 20/40 or Better at Week 24
Proportion of Participants with BCVA Snellen Equivalent of 20/40 or Better Over Time
Proportion of Participants with BCVA Snellen Equivalent of 20/200 or Worse at Week 24
Proportion of Participants with BCVA Snellen Equivalent of 20/200 or Worse Over Time
Change in National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Version Composite Score Over Time
Number of Participants who Experience a Systemic Adverse Event (AE)
Number of Participants who Experience an Ocular Adverse Event (AE)
Number of Participants who Discontinue Study Treatment Due to an AE
Number of Participants with Antidrug Antibodies (ADA) to MK-8748
Maximum Plasma Concentration (Cmax) of MK-8748
Plasma Trough Concentration (Ctrough) of MK-8748